84 related articles for article (PubMed ID: 12110330)
1. Cytotoxic T lymphocyte epitope analogues containing cis- or trans-4-aminocyclohexanecarboxylic acid residues.
Marastoni M; Bazzaro M; Micheletti F; Gavioli R; Tomatis R
Bioorg Med Chem; 2002 Sep; 10(9):3061-6. PubMed ID: 12110330
[TBL] [Abstract][Full Text] [Related]
2. Peptide analogues of a subdominant epitope expressed in ebv-associated tumors: synthesis and immunological activity.
Marastoni M; Bazzaro M; Micheletti F; Gavioli R; Tomatis R
J Med Chem; 2001 Jul; 44(14):2370-3. PubMed ID: 11428932
[TBL] [Abstract][Full Text] [Related]
3. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
Micheletti F; Guerrini R; Formentin A; Canella A; Marastoni M; Bazzaro M; Tomatis R; Traniello S; Gavioli R
Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
[TBL] [Abstract][Full Text] [Related]
4. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
[TBL] [Abstract][Full Text] [Related]
5. Design of dimeric peptides obtained from a subdominant Epstein-Barr virus LMP2-derived epitope.
Marastoni M; Bazzaro M; Gavioli R; Micheletti F; Traniello S; Tomatis R
Eur J Med Chem; 2000 Jun; 35(6):593-8. PubMed ID: 10906411
[TBL] [Abstract][Full Text] [Related]
6. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
7. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.
Lee SP; Thomas WA; Blake NW; Rickinson AB
Eur J Immunol; 1996 Aug; 26(8):1875-83. PubMed ID: 8765034
[TBL] [Abstract][Full Text] [Related]
8. Supra-agonist peptides enhance the reactivation of memory CTL responses.
Micheletti F; Canella A; Vertuani S; Marastoni M; Tosi L; Volinia S; Traniello S; Gavioli R
J Immunol; 2000 Oct; 165(8):4264-71. PubMed ID: 11035060
[TBL] [Abstract][Full Text] [Related]
9. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
10. Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein.
Sauma SY; Gammon MC; Bednarek MA; Cunningham B; Biddison WE; Hermes JD; Porter G; Tamhankar S; Hawkins JC; Bush BL
Hum Immunol; 1993 Aug; 37(4):252-8. PubMed ID: 8300410
[TBL] [Abstract][Full Text] [Related]
11. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
12. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
[TBL] [Abstract][Full Text] [Related]
13. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
Gavioli R; Vertuani S; Masucci MG
Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
[TBL] [Abstract][Full Text] [Related]
15. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
[TBL] [Abstract][Full Text] [Related]
16. An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.
Bell MJ; Abbott RJ; Croft NP; Hislop AD; Burrows SR
J Virol; 2009 Mar; 83(6):2783-8. PubMed ID: 19129449
[TBL] [Abstract][Full Text] [Related]
17. Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes.
Bodmer H; Ogg G; Gotch F; McMichael A
Nature; 1989 Nov; 342(6248):443-6. PubMed ID: 2479838
[TBL] [Abstract][Full Text] [Related]
18. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
19. Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype.
Burrows SR; Elkington RA; Miles JJ; Green KJ; Walker S; Haryana SM; Moss DJ; Dunckley H; Burrows JM; Khanna R
J Immunol; 2003 Aug; 171(3):1407-12. PubMed ID: 12874232
[TBL] [Abstract][Full Text] [Related]
20. Induction of the Epstein-Barr virus latent membrane protein 2 antigen-specific cytotoxic T lymphocytes using human leukocyte antigen tetramer-based artificial antigen-presenting cells.
Lu XL; Liang ZH; Zhang CE; Lu SJ; Weng XF; Wu XW
Acta Biochim Biophys Sin (Shanghai); 2006 Mar; 38(3):157-63. PubMed ID: 16518539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
